Further, GSVA was carried out on the two PCa subtypes using the HALLMARKS50 gene set, and the results showed that some cancer‐promoting pathways, such as oestrogen response, epithelial‐mesenchymal transition and KRAS signalling, significantly enriched the subtypes with worse clinical outcomes (Figure 3A). This evidence concerns the gene KRAS and cancer.